focus -WSS

focus

author：leisure time 2025-09-29 22:38:11 - browse：2713

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Listen: BridgeBio's big week & Lilly's Alzheimer's data

WSS

Medicaid rebukes states for mistakenly disenrolling children

How to protect patients from sexual assault

New chart reveals military’s vast involvement in Operation Warp Speed

Why Novartis is changing the name of its research labs

Medicaid rebukes states for mistakenly disenrolling children

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

hotspot

focus

explore

In age of alternative facts, a scholarly course on calling out crap

How to fix cancer clinical trials' diversity problem

Affirmative action in medical school literally saved lives

Crinetics acromegaly drug succeeds in late

Trump demands the U.S. pay no more for drugs than other countries … again

What American doctors can learn from their Israeli counterparts

State Dept. review finds Biden bears some blame for Afghanistan failures

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

How to save PrEP access — and even expand it

Reframing the conversation around gain

focus

Weighted lottery helped low

How Brent Saunders' Allergan experiment failed

How to fix cancer clinical trials' diversity problem

What American doctors can learn from their Israeli counterparts

What is the Turing Test that determines if computers can think?

What is artificial intelligence? Experts weigh in

explore

leisure time

leisure time

entertainment